| 臺大學術典藏 |
2021-07-03T03:34:25Z |
Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells
|
Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:23Z |
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells
|
Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; Cheng A.-L.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:22Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:13Z |
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model
|
Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:12Z |
Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma
|
Tai W.-T.; Shiau C.-W.; PEI-JER CHEN; Chu P.-Y.; Huang H.-P.; Liu C.-Y.; Huang J.-W.; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:33:59Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; PEI-JER CHEN; Chen K.-F.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:33:49Z |
Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))
|
Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:33:47Z |
Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))
|
Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:33:43Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; PEI-JER CHEN; Chen D.-S.; Chen K.-F.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:42Z |
Corrigendum to “Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity” (Eur. J. Med. Chem. (2012) 55 (220–227)(S0223523412004497)(10.1016/j.ejmech.2012.07.023))
|
Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN; Kim I.; Shiau C.-W. |
| 臺大學術典藏 |
2021-06-24T01:53:53Z |
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
|
Su J.-C.; Mar A.-C.; Wu S.-H.; Tai W.-T.; Chu P.-Y.; Wu C.-Y.; Tseng L.-M.; Lee T.-C.; Chen K.-F.; Liu C.-Y.; HAO-CHIEH CHIU; Shiau C.-W. |
| 臺大學術典藏 |
2021-06-03T06:50:19Z |
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
|
Chen K.-F.; Tai W.-T.; Liu T.-H.; HSIANG-PO HUANG; Lin Y.-C.; Shiau C.-W.; Li P.-K.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2021-06-03T06:50:19Z |
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
|
Tai W.-T.; Cheng A.-L.; Shiau C.-W.; HSIANG-PO HUANG; Huang J.-W.; Chen P.-J.; Chen K.-F. |
| 臺大學術典藏 |
2021-06-03T06:50:16Z |
Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma
|
Tai W.-T.; Shiau C.-W.; Chen P.-J.; Chu P.-Y.; HSIANG-PO HUANG; Liu C.-Y.; Huang J.-W.; Chen K.-F. |
| 臺大學術典藏 |
2021-06-03T06:50:15Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Su T.-H.;Shiau C.-W.;Jao P.;Liu C.-H.;Liu C.-J.;Tai W.-T.;Jeng Y.-M.;Yang H.-C.;Tseng T.-C.;Hsiang-Po Huang;Cheng H.-R.;Chen P.-J.;Chen K.-F.;Kao J.-H.;Chen D.-S.; Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; HSIANG-PO HUANG; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-05-24T07:20:35Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Su T.-H.; Shiau C.-W.; Jao P.; CHEN-HUA LIU; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-05-24T07:20:29Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; CHEN-HUA LIU; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-18T08:20:17Z |
Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3
|
CHAO-YUAN HUANG; Lin C.-S.; Tai W.-T.; Hsieh C.-Y.; Shiau C.-W.; Cheng A.-L.; Chen K.-F. |
| 臺大學術典藏 |
2021-05-18T08:20:15Z |
Dovitinib acts as a novel radiosensitizer in hepatocellular carcinoma by targeting SHP-1/STAT3 signaling
|
CHAO-YUAN HUANG; Tai W.-T.; Wu S.-Y.; Shih C.-T.; Chen M.-H.; Tsai M.-H.; Kuo C.-W.; Shiau C.-W.; Hung M.-H.; Chen K.-F. |
| 臺大學術典藏 |
2021-05-18T08:20:15Z |
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3
|
CHAO-YUAN HUANG; Tai W.-T.; Hsieh C.-Y.; Hsu W.-M.; Lai Y.-J.; Chen L.-J.; Shiau C.-W.; Chen K.-F. |
| 臺大學術典藏 |
2021-03-19T01:54:21Z |
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
|
Chen K.-F.; Tai W.-T.; TSUNG-HAO LIU; Huang H.-P.; Lin Y.-C.; Shiau C.-W.; Li P.-K.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T01:47:37Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
TUNG-HUNG SU; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-03-09T01:43:24Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
TUNG-HUNG SU; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; Kao J.-H. |
| 臺大學術典藏 |
2020-06-19T02:27:03Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
Su T.-H.;Shiau C.-W.;Jao P.;Yang N.-J.;Tai W.-T.;Liu C.-J.;Tseng T.-C.;Yang H.-C.;Liu C.-H.;Kai-Wen Huang;Hu T.-C.;Huang Y.-J.;Wu Y.-M.;Chen L.-J.;Chen P.-J.;Chen D.-S.;Chen K.-F.;Kao J.-H.; Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; KAI-WEN HUANG; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; Kao J.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:27Z |
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
|
Chen K.-F. ;Chen H.-L. ;Tai W.-T. ;Feng W.-C. ;Chih-Hung Hsu ;Chen P.-J. ;Cheng A.-L.; Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; CHIH-HUNG HSU; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-26T06:54:22Z |
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer
|
Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN; Shiau C.-W.; Yu C.-J.; Chen K.-F. |
| 臺大學術典藏 |
2020-03-06T08:25:00Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Liu C.-H.; Liu C.-J.; Tai W.-T.; YUNG-MING JENG; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S.; Su T.-H.;Shiau C.-W.;Jao P.;Liu C.-H.;Liu C.-J.;Tai W.-T.;Yung-Ming Jeng;Yang H.-C.;Tseng T.-C.;Huang H.-P.;Cheng H.-R.;Chen P.-J.;Chen K.-F.;Kao J.-H.;Chen D.-S.; Su T.-H.; Shiau C.-W.; Jao P. |
| 臺大學術典藏 |
2020-02-11T07:58:33Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
Su T.-H.;Shiau C.-W.;Jao P.;Yang N.-J.;Tai W.-T.;Liu C.-J.;Tseng T.-C.;Yang H.-C.;Liu C.-H.;Huang K.-W.;Hu T.-C.;Huang Y.-J.;Yao-Ming Wu;Chen L.-J.;Chen P.-J.;Chen D.-S.;Chen K.-F.;Kao J.-H.; Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; YAO-MING WU; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; Kao J.-H. |
| 臺大學術典藏 |
2018-09-10T15:35:00Z |
Dovitinib acts as a novel radiosensitizer in hepatocellular carcinoma by targeting SHP-1/STAT3 signaling
|
Huang, C.-Y.;Tai, W.-T.;Wu, S.-Y.;Shih, C.-T.;Chen, M.-H.;Tsai, M.-H.;Kuo, C.-W.;Shiau, C.-W.;Hung, M.-H.;Chen, K.-F.; Huang, Chao-Yuan; CHAO-YUAN HUANG; Tai, Wei-Tien; Wu, Szu-Yuan; Shih, Chih-Ting; Chen, Min-Hsuan; Tsai, Ming-Hsien; Kuo, Chiung-Wen; Shiau, Chung-Wai; Hung, Man-Hsin; Chen, Kuen-Feng |
| 臺大學術典藏 |
2018-09-10T09:39:54Z |
SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells
|
Wang, C.-T.;Lin, C.-S.;Shiau, C.-W.;Chu, P.-Y.;Hsiao, C.-C.;Chiang, Y.-L.;Tai, W.-T.;Chen, K.-F.; Wang, C.-T.; Lin, C.-S.; Shiau, C.-W.; Chu, P.-Y.; Hsiao, C.-C.; Chiang, Y.-L.; Tai, W.-T.; Chen, K.-F.; CHEN-SI LIN; Kuen-Feng Chen |
| 臺大學術典藏 |
2018-09-10T09:39:54Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen, K.-F.;Chen, H.-L.;Shiau, C.-W.;Liu, C.-Y.;Chu, P.-Y.;Tai, W.-T.;Ichikawa, K.;Chen, P.-J.;Cheng, A.-L.; PEI-JER CHEN; Kuen-Feng Chen; ANN-LII CHENG |
| 臺大學術典藏 |
2018-09-10T08:41:21Z |
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
|
Chen, K.-F.;Tai, W.-T.;Huang, J.-W.;Hsu, C.-Y.;Chen, W.-L.;Cheng, A.-L.;Chen, P.-J.;Shiau, C.-W.; PEI-JER CHEN; Kuen-Feng Chen; ANN-LII CHENG |
| 國立臺灣大學 |
2012 |
Activation of tyrosine phosphatase SHP-1 determines the apoptotic effect of sorafenib on HCC cells.
|
Tai, W-T.; Shiau, C-W.; Cheng, A-L.; Chen, P-J.; Chen, K-F.; 陳昆鋒; 陳培哲 |
| 國立臺灣科技大學 |
2006 |
Organizational justice, motivation to learn, and training outcomes
|
Liao, W.-C.;Tai, W.-T. |
| 國立臺灣大學 |
2005-05 |
An investigation of individual and contextual factors influencing training variables.
|
Chuang, A.; Liao, W. C.; Tai, W. T. |
| 國立臺灣科技大學 |
2005 |
An investigation of individual and contextual factors influencing training variables
|
Chuang, A.;Liao, W.C.;Tai, W.T. |
